Ugandan unit of Cipla raises $43.8 mln in IPO - Renaissance Capital
Cipla Quality Chemical Industries Ltd (CQCIL), majority owned by India's third-largest drugmaker, sold 657 million shares equivalent to 18 per cent of the firm's total equity. Each share in the IPO was priced at 256.5 shillings.
Cipla Quality Chemical Industries Ltd (CQCIL), majority owned by India's third-largest drugmaker, sold 657 million shares equivalent to 18 per cent of the firm's total equity. Each share in the IPO was priced at 256.5 shillings.
John Porter, the chief business officer at investment bank Renaissance Capital, told Reuters interest came from local and international investors.
"The offering has been oversubscribed with the major part of the demand coming from blue-chip Sub-Saharan Africa investors," Porter said, speaking during a function to launch the firm's debut trading on Uganda Securities Exchange (USE).
He did not say by how much the IPO was oversubscribed.
Cipla Quality Chemical Industries Ltd, established in 2005, has a factory in Uganda's capital Kampala and makes a range of drugs including antiretrovirals, anti-malaria and drugs to treat Hepatitis B and C. Most of the drugs are sold in Sub-Saharan Africa.
The IPO is the first on Ugandan bourse, a small exchange of about 17 equities, since 2012 when the country's sole power distributor Umeme Ltd went public.
KAMPALA: The Ugandan unit of India's pharmaceutical giant Cipla raised 167 billion Ugandan shillings ($43.8 million) from its oversubscribed initial public offering (IPO), an investment bank that helped advise on the transaction said.
Cipla Quality Chemical Industries Ltd (CQCIL), majority owned by India's third-largest drugmaker, sold 657 million shares equivalent to 18 per cent of the firm's total equity. Each share in the IPO was priced at 256.5 shillings.
John Porter, the chief business officer at investment bank Renaissance Capital, told Reuters interest came from local and international investors.
"The offering has been oversubscribed with the major part of the demand coming from blue-chip Sub-Saharan Africa investors," Porter said, speaking during a function to launch the firm's debut trading on Uganda Securities Exchange (USE).
He did not say by how much the IPO was oversubscribed.
Cipla Quality Chemical Industries Ltd, established in 2005, has a factory in Uganda's capital Kampala and makes a range of drugs including antiretrovirals, anti-malaria and drugs to treat Hepatitis B and C. Most of the drugs are sold in Sub-Saharan Africa.
The IPO is the first on Ugandan bourse, a small exchange of about 17 equities, since 2012 when the country's sole power distributor Umeme Ltd went public.
anti-malariaantiretroviralsCiplacipla IPOCipla Quality Chemical IndustriesCipla Quality Chemical Industries LtdCipla share priceCQCILHepatitis B and Cinitial public offeringIPOJohn PorterKampalaRenaissance CapitalUganda Securities Exchangeuse
Source : ReutersMedical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd